GlassScriptPhysician profile
Laurie M Holubeck
NPI 1912055203
$1,338.74
in general payments reported to CMS, 2019-2025
18 companies · $274 in 2025
The $274 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.63 · 2020: $18.75 · 2021: $28.35 · 2022: $140 · 2023: $310 · 2024: $510 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $346.53 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $209.84 | 2023-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $131.24 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Pfizer INC. | $87.14 | 2022-2025 | |
| Noven Therapeutics, LLC | $84.78 | 2023-2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $81.66 | 2020-2024 | |
| Collegium Pharmaceutical, INC. | $80.52 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $49.61 | 2023-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Tris Pharma INC | $48.11 | 2022-2023 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $43.49 | 2023 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $34.55 | 2024 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $26.69 | 2019-2021 | |
| Alk-Abello, INC | $23.69 | 2025 | Neffy, Grastek, Odactra |
| Ars Pharmaceuticals Operations, INC. | $21.36 | 2025 | Neffy |
| Biomerieux INC | $19.90 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $17.39 | 2019 | |
| Shire North American Group INC | $16.24 | 2019 | |
| Kaleo, INC. | $16.00 | 2023 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Holubeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.